Bluebird CFO Leaves The Nest As Company Reveals Grim Cash Position
Pressure On For Approvals To Shore Up Financing
Its Q4 earnings report was not the first time that bluebird mentioned selling priority review vouchers it has not received yet, but the PRV revenue is needed to fund operations beyond 2022.
You may also be interested in...
The firm is laying off a big piece of its workforce and deprioritizing some investments to free up capital for potential upcoming launches, but that could add commercial risks.
The FDA placed a partial hold on its clinical program for lovo-cel due to an adolescent patient experiencing anemia 18 months after treatment, raising uncertainty over filing plans.
Public Company Edition: Blade will merge with a special purpose acquisition corporation to go public, Bluebird spins out 2seventy with $442m in cash and Compass raises $125m in a move to the Nasdaq.